Coronavirus: USask researchers expect human clinical trials for vaccine in the fall

USask researchers expect human clinical trials for vaccine in the fall
WATCH: Ferrets and hamsters have been responding well to a vaccine developed by USask researchers.

University of Saskatchewan’s (USask) Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac) team has seen promising results in their clinical trials for a COVID-19 vaccine.

The team began research in early January, starting the day the World Health Organization (WHO) announced there was a new disease spreading in China.

They started by finding a sequence for SARS-CoV-2, the virus causing COVID-19, before designing a vaccine for it. The vaccine has been tested on ferrets and hamsters.

READ MORE: A look at research being done in Canada for a coronavirus vaccine

“For respiratory diseases in general, they’re a very good model,” USask VIDO-InterVac director and CEO Volker Gerdts explained.

“For this one, the virus uses receptors to get into the O cells and the receptors in ferrets are very similar to the receptors we find in humans.”

Story continues below advertisement

READ MORE: Coronavirus: Indigenous health authorities tell HoC committee more PPE needed

The animals showed a strong immune response to SARS-CoV-2 when vaccinated. They generated neutralizing antibodies and the infection was nearly undetectable in the respiratory tract.

Twenty-four animals have been tested showing these results. The research team will continue tests on animals, but have made enough progress to start thinking about testing the vaccine on people.

Coronavirus outbreak: Health Canada approves first clinical trial for possible coronavirus vaccine
Coronavirus outbreak: Health Canada approves first clinical trial for possible coronavirus vaccine

Safety studies will be developed this summer.

[ Sign up for our Health IQ newsletter for the latest coronavirus updates ]

“That’s very important to demonstrate that the vaccine is safe for use in humans,” Gerdts said.

“To that end, we have already been manufacturing the material that the clinical grade that you need to use in humans.”

Story continues below advertisement
Update on VIDO-InterVac’s COVID-19 vaccine
Update on VIDO-InterVac’s COVID-19 vaccine

Gerdts said his team has already received over 20 inquiries with interest in being tested.

Once deemed safe, human clinical trials will be coordinated by a research unit at Halifax’s Dalhousie University.

Tests will be done on a volunteer basis across the country and are expected to begin in the fall. Researchers hope to test different age groups and people with different health backgrounds.

VIDO-InterVac’s COVID-19 vaccine development has been funded provincially and federally.

READ MORE: Makers of 1st coronavirus vaccine in Saskatchewan get $28M in federal, provincial funding

Story continues below advertisement

Questions about COVID-19? Here are some things you need to know:

Symptoms can include fever, cough and difficulty breathing — very similar to a cold or flu. Some people can develop a more severe illness. People most at risk of this include older adults and people with severe chronic medical conditions like heart, lung or kidney disease. If you develop symptoms, contact public health authorities.

To prevent the virus from spreading, experts recommend frequent handwashing and coughing into your sleeve. They also recommend minimizing contact with others, staying home as much as possible and maintaining a distance of two metres from other people if you go out.

For full COVID-19 coverage from Global News, click here.